US EditionStandard BioTools Inc. (LAB) Stock Analysis: Exploring A Potential 75.93% Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Standard BioTools Inc. (LAB) Stock Analysis: Exploring A Potential 75.93% Upside
Standard BioTools Inc. (NASDAQ: LAB), a key player in the healthcare sector’s medical devices industry, has been catching the eye of investors due to its promising potential upside. With a current market capitalization of $487.68 million and a stock price of $1.35, the company presents an intriguing opportunity, particularly as analysts have set an average target price of $2.38, indicating a potential upside of 75.93%. Founded in 1999 and headqu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
